However, an early clinical trial examining mTORC1 inhibitors in human CRC patients demonstrated modest results, perhaps due to loss of an mTORC1-dependent feedback loop that limits PI3K activation and/or continued mTORC2-mediated activation of AKT [3], [60]. This evidence concerns the gene AKT1 and colorectal carcinoma.